SCHEMBL22276170

SCHEMBL22276170

O=C(NC1(C23CC(C(=O)O)(C2)C3)CC1)c1cccc2ccn(Cc3ccc4ccccc4n3)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 3/20 0.41
PTGDR Q13258 3/20 0.41
TBXA2R P21731 1/20 0.41
PTGER1 P34995 1/20 0.41
PTGFR P43088 1/20 0.41
PTGER3 P43115 1/20 0.41
PTGER2 P43116 1/20 0.41
HDAC1 Q13547 2/20 0.38
HDAC11 Q96DB2 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
FAAH O00519 3/20 0.38
TLR7 Q9NYK1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29406110 1.00 PTGER4 (0.41) PTGER4PTGDRTBXA2RPTGER1PTGFR
SCHEMBL22276245 0.88 PTGER4 (0.40) PTGER4PTGDRTBXA2RPTGER1PTGFR
SCHEMBL22276163 0.85 PTGER4 (0.39) PTGER4PTGDRTBXA2RPTGER1PTGFR
SCHEMBL22276151 0.83 PTGER4 (0.39) PTGER4PTGDRTBXA2RPTGER1PTGFR
SCHEMBL22276026 0.83 TBXA2R (0.39) PTGER4PTGDRTBXA2RPTGER1PTGFR
SCHEMBL29402821 0.82 PTGER4 (0.37) PTGER4PTGDRTBXA2RPTGER1PTGFR
SCHEMBL22276145 0.82 PTGER4 (0.37) PTGER4PTGDRTBXA2RPTGER1PTGFR
SCHEMBL22276178 0.82 PTGER4 (0.38) PTGER4PTGDRTBXA2RPTGER1PTGFR
SCHEMBL23879087 0.81 PTGER4 (0.51) PTGER4PTGDRTBXA2RPTGER1PTGFR
SCHEMBL29403043 0.81 PTGER4 (0.51) PTGER4PTGDRTBXA2RPTGER1PTGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12240812-B2 Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) 2025-03-04 US disclosed
EP-3889134-B1 COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF KEYTHERA SUZHOU PHARMACEUTICALS CO LTD (CN) 2024-09-25 EP disclosed
EP-3889134-A1 COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) 2021-10-06 EP disclosed
WO-2020151566-A1 COMPOUND FOR INHIBITING PGE2/EP4 SIGNALING TRANSDUCTION INHIBITING, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF 凯复制药有限公司 2020-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240812-B2 Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof PTGER4, PTGER1, PTGES PTGER4 1/4885PTGDR 15/4885TBXA2R 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.